James W. Simpkins – författare
Visar alla böcker från författaren James W. Simpkins. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
550 kr
Skickas inom 10-15 vardagar
Alzheimer's disease is one the foremost health problems facing every society fortunate enough to attain a level of medical care that ensures an average lifespan of over 70 years of age. The cause of the disease remains unknown, and no single therapeutic approach has yet been found highly efficacious. Indeed, as the complexity of its effects on brain neuronal systems becomes elucidated, the concept emerges that Alzheimer's disease may be an umbrella term for multiple Alzheimer's-type syndromes that can be differentiated based on etiology (hereditary versus sporadic), neurochemical deficits, and extent of pathology. Whether one or more disease processes is involved, it seems increasingly unlikely that any single drug will provide efficacious relief across the broad spectrum of symptoms reflected in large subject populations. Rational therapeutic approaches may yield long term amelioration of many symptoms in selected groups of patients; and individual symptoms may be ameliorated in larger populations. Multiple approaches may be combined to optimize therapeutic effects. For example, a variety of approaches remain focused on restoration of cholinergic neurodegeneration and enhancing cholinergic neurotransmission, whereas other approaches attempt to retard the of the brain that occurs during Alzheimer's disease. Chapters cover continuous degeneration topics from growth factor secretion of proteases, which could modify amyloid processing, to neuronal gene delivery using viral vectors. The breadth and thoroughness of the chapters truly embrace a broad spectrurn of models, pathological mechanisms and therapeutic approaches.
Future of Hormone Therapy
What Basic Science and Clinical Studies Teach Us, Volume 1052
Häftad, Engelska, 2006
1 283 kr
Tillfälligt slut
This volume brings together contributions from basic scientists, epidemiologists, and practicing clinicians whose expertise or clinical practice involves the study or administration of gonadal hormones. Our current knowledge of the biology of gonadal hormones is assessed, and the question is explored of the gaps in knowledge that need to be addressed through additional research. Other questions explored include the following: What is the appropriate population to study? What is the therapeutic window for hormone therapy and/or estrogen therapy? What are the appropriate formulations of HT and ET? What should be considered the most appropriate design for clinical trials that address the efficacy of HT/ET? What are appropriate surrogate markers of neurological decline/impairment? What are the best in vitro and in vivo models to address the efficacy of postmenopausal HT or ET? NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.